Susan Chimonas and Jerome Kassirer argue that giving out “free” drug samples is not effective in improving drug access for the indigent, does not promote rational drug use, and raises the cost of care

DM Morelli

E Jordan

EJ Topol

EL Backer

F Charatan

GC Alexander

Jerome P. Kassirer

JM Westfall

K Johnson

KEM Groves

KL Tong

LD Chew

M Petersen

M-A Gagnon

MA Morgan

MB Rosenthal

MR Limcangco

MY Peay

R Pear

RF Adair

S Poser

SL Cutrona

Susan Chimonas

Crossref

Directory of Open Access Journals

PubMed Central

English

[No authors listed]

[No authors listed] (2006) Samples. Cafe ´ Pharma message boards.

[No authors listed] (2007) Restricting samples.

A physician survey of the effect of drug sample availability on physicians’ behavior.

Characteristics of recipients of free prescription drug samples: A nationally representative analysis.

Do drug samples influence resident prescribing behavior? A randomized trial.

Do pharmaceutical representatives misuse their drug samples?

Do physicians use drug samples to increase access for needy patients? [abstract].

Failing the public health—

Free drug samples in the United States: Characteristics of pediatric recipients and safety concerns.

Growing opposition to free drug samples; Ultimate costs and safety are cited. The New York Times. Available: http://query.nytimes.

Interactions of doctors with the pharmaceutical industry.

Personal use of drug samples by physicians and office staff.

PhRMA defends distribution of pharmaceutical samples. Available: http://www. phrma.org/news_room/press_releases/phrma_ defends_distribution_of_pharmaceutical_samples.

PhRMA statement on free pharmaceutical samples. Available: http://www. phrma.org/news_room/press_releases/phrma_ statement_on_free_pharmaceutical_samples/.

Prescription drug samples—Does this marketing strategy counteract policies for quality use of medicines?

Sample medication dispensing in a residency practice.

The role of commercial sources in the adoption of a new drug.

The value of pharmaceutical representative visits and medication samples in community-based family practices.

Unlabeled prescription drug samples and the ‘learned intermediary’: The case for liability without preemption.

No More Free Drug Samples?